{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 64,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "roadmap",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 10,
  "notes": "The slide uses a standard pharmaceutical pipeline table format, categorizing by clinical vs preclinical status and highlighting specific regulatory designations and trial results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/27",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.96,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Note: 95% overall response rate in multiple myeloma... [full source text]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74fbeaf6-9351-4824-a3f8-22675a2e4f78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.96,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "table",
      "text": "Pipeline table with columns: Stage, Tx Type, Candidate, Indication, Preclinical, Phase 1, Phase 2, Phase 3, Approval, Progress, Global Rights",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8c7a31a-270a-4cfa-b0b4-7cac190f8db5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "ImmixBio Pipeline Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1faee4f-4495-4c0c-9695-6cfb6014947a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "79d35e9b-2249-48ed-add9-22b9f6345f32",
      "evidence": "The pipeline table uses horizontal bars to represent development stages over time.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 24,
      "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 27,
      "from": 23,
      "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The clinical development plan and upcoming catalysts are outlined.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}